ATE342720T1 - Kombination aus quetiapin und zolmitriptan - Google Patents
Kombination aus quetiapin und zolmitriptanInfo
- Publication number
- ATE342720T1 ATE342720T1 AT02760969T AT02760969T ATE342720T1 AT E342720 T1 ATE342720 T1 AT E342720T1 AT 02760969 T AT02760969 T AT 02760969T AT 02760969 T AT02760969 T AT 02760969T AT E342720 T1 ATE342720 T1 AT E342720T1
- Authority
- AT
- Austria
- Prior art keywords
- zolmitriptan
- quetiapine
- combination
- sub
- treatment
- Prior art date
Links
- 229960004431 quetiapine Drugs 0.000 title abstract 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title abstract 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title abstract 2
- 229960001360 zolmitriptan Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102855A SE0102855D0 (sv) | 2001-08-27 | 2001-08-27 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE342720T1 true ATE342720T1 (de) | 2006-11-15 |
Family
ID=20285147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02760969T ATE342720T1 (de) | 2001-08-27 | 2002-08-23 | Kombination aus quetiapin und zolmitriptan |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20050020571A1 (enExample) |
| EP (1) | EP1423112B1 (enExample) |
| JP (1) | JP2005503391A (enExample) |
| AT (1) | ATE342720T1 (enExample) |
| AU (1) | AU2002326271B2 (enExample) |
| CA (1) | CA2456480A1 (enExample) |
| DE (1) | DE60215525T2 (enExample) |
| ES (1) | ES2274081T3 (enExample) |
| NZ (1) | NZ530930A (enExample) |
| SE (1) | SE0102855D0 (enExample) |
| WO (1) | WO2003018009A1 (enExample) |
| ZA (1) | ZA200401550B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522344A1 (en) * | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| US7495024B2 (en) | 2006-08-07 | 2009-02-24 | Via Pharmaceuticals, Inc. | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque |
| US20110212980A1 (en) * | 2008-10-22 | 2011-09-01 | Novartis Ag | Combinations for the treatment of migraine |
| US20110091435A1 (en) * | 2008-10-24 | 2011-04-21 | University Of Southern California | Phytoestrogenic formulations for alleviation or prevention of hair loss |
| US10457299B2 (en) * | 2017-02-22 | 2019-10-29 | Westinghouse Air Brake Technologies Corporation | Train stop timer |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| EP0906104A4 (en) * | 1996-03-25 | 2003-12-10 | Lilly Co Eli | PAIN TREATMENT PROCESS |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| GB9709815D0 (en) * | 1997-05-14 | 1997-07-09 | Merck Sharp & Dohme | Therapeutic method |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
-
2001
- 2001-08-27 SE SE0102855A patent/SE0102855D0/xx unknown
-
2002
- 2002-08-23 AU AU2002326271A patent/AU2002326271B2/en not_active Ceased
- 2002-08-23 ES ES02760969T patent/ES2274081T3/es not_active Expired - Lifetime
- 2002-08-23 US US10/487,701 patent/US20050020571A1/en not_active Abandoned
- 2002-08-23 DE DE60215525T patent/DE60215525T2/de not_active Expired - Lifetime
- 2002-08-23 EP EP02760969A patent/EP1423112B1/en not_active Expired - Lifetime
- 2002-08-23 JP JP2003522527A patent/JP2005503391A/ja active Pending
- 2002-08-23 CA CA002456480A patent/CA2456480A1/en not_active Abandoned
- 2002-08-23 NZ NZ530930A patent/NZ530930A/en not_active IP Right Cessation
- 2002-08-23 AT AT02760969T patent/ATE342720T1/de not_active IP Right Cessation
- 2002-08-23 WO PCT/SE2002/001507 patent/WO2003018009A1/en not_active Ceased
-
2004
- 2004-02-25 ZA ZA200401550A patent/ZA200401550B/en unknown
-
2007
- 2007-11-07 US US11/936,244 patent/US20080108596A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050020571A1 (en) | 2005-01-27 |
| DE60215525D1 (de) | 2006-11-30 |
| EP1423112A1 (en) | 2004-06-02 |
| US20080108596A1 (en) | 2008-05-08 |
| AU2002326271B2 (en) | 2007-10-11 |
| WO2003018009A1 (en) | 2003-03-06 |
| JP2005503391A (ja) | 2005-02-03 |
| ES2274081T3 (es) | 2007-05-16 |
| DE60215525T2 (de) | 2007-06-06 |
| SE0102855D0 (sv) | 2001-08-27 |
| NZ530930A (en) | 2006-01-27 |
| ZA200401550B (en) | 2004-11-17 |
| EP1423112B1 (en) | 2006-10-18 |
| CA2456480A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| SE0104341D0 (sv) | New use | |
| ATE384058T1 (de) | Thiazolderivate | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| DE60209511D1 (de) | Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| EE05419B1 (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| MXPA02012272A (es) | Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv. | |
| MXPA05008838A (es) | Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. | |
| HUS1700053I1 (hu) | Staurosporin-származékok új gyógyászati alkalmazásai | |
| UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
| DE60205455T2 (de) | Naphthyridinderivate | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| TW200517107A (en) | Novel formulation | |
| TW200616608A (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
| DE60215525D1 (de) | Kombination aus quetiapin und zolmitriptan | |
| ATE373644T1 (de) | N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika | |
| EP1784173A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC BONE DISEASES WITH ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | |
| SE0000303D0 (sv) | Novel compounds | |
| BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |